Giant negative T waves during interferon therapy in a patient with chronic hepatitis c

Internal Medicine

Volumn 40, Issue 2, 2001, Pages 105-109

  Fujiwara, Takayuki ^a   Kiura, Katsuyuki ^a   Ochi, Koji ^a   Matsubara, Hiromi ^a   Yamanari, Hiroshi ^a   Shimomura, Hiroyuki ^a   Harada, Mine ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Giant negative T waves; Hypertension; Interferon

Indexed keywords

ALPHA INTERFERON;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CASE REPORT; CHRONIC ACTIVE HEPATITIS; DEPRESSION; DISEASE COURSE; ECHOCARDIOGRAPHY; FATIGUE; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE HYPERTROPHY; HEPATITIS C; HUMAN; HYPERTENSION; JAPAN; MALE; T WAVE;

EID: 0035080584     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.40.105     Document Type: Article

References (17)

1. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf 10: 115-150, 1994.
2. Spiegel RJ. The alpha interferons: Clinical overview. Semin in Oncol 14: 1-12, 1987.
3. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol 14: 38-47, 1996.
4. Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest 99: 557-561, 1991.
5. Marcellin P, Boyer N, Giostra E, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 13: 393-397, 1991 (see comments).
6. Teragawa H, Hondo T, Amano H, Hino F, Ohbayashi M. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J 37: 905-915, 1996.
7. Kawada Y, Hiro T, Fukuta S, Sakamura T, Matszaki M, Okada K. A case of various cardiac disorders due to interferon-alpha, Nippon Naika Gakkai Zasshi (J Jpn Soc Int Med) 85: 276-278, 1996 (in Japanese).
8. Omae A, Katayama K, Kakiuchi Y, et al. A case of ventricular tachycardia occurred during IFN therapy for chronic active hepatitis C, Nippon Naika Gakkai Zasshi (J Jpn Soc Int Med) 84: 1734-1735, 1995 (in Japanese).
9. Teragawa H, Hondo T, Amano H, et al. Cardiogenic shock following recombinant alpha-2b interferon therapy for chronic hepatitis C. Jpn Heart J 37: 137-142, 1996.
10. Sasaki M, Sata M, Suzuki H, Tanikawa K. A case of chronic hepatitis C with sinus bradycardia during IFN therapy. Kurume Med J 45 (1): 161-163, 1998.
11. Matsumori A, Matoba Y, Nishio R, Shioi T, Ono K, Sasayama S. Detection of hepatitis C virus RNA from the heart of patients with hypertrophic cardiomyopathy Biochem Biophys Res Commun 222 (3): 678-682, 1996.
12. Matsumori A, Ohashi N, Hasegawa K, et al. Hepatitis C virus infection and heart diseases: A multicenter study in Japan. Jpn Circ J 62 (5): 389-391, 1998.
13. Matsumori A, Ohashi N, Sasayama S. Hepatitis C virus infection and hypertrophic cardiomyopathy. Ann Intern Med 129 (9): 749-750, 1998 (letter).
14. Matsumori A, Ohashi N, Nishio R, et al. Apical hypertrophic cardiomyopathy and hepatitis C virus infection. Jpn Circ J 63 (6): 433-438, 1999.
15. Dalekos GN, Achenbach K, Christodoulou D, et al. Idiopathic dilated cardiomyopathy: Lack of association with hepatitis C virus infection. Heart 80 (3): 270-275, 1998.
16. Grumbach IM, Heermann K, Figulla HR. Low prevalence of hepatitis C virus antibodies and RNA in patients with myocarditis and dilated cardiomyopathy Cardiology 90 (2): 75-78, 1998.
17. Prati D, Poli F, Farma E, et al. Multicenter study on hepatitis C virus infection in patients with dilated cardiomyopathy. North Italy Transplant Program (NITP). J Med Virol 58 (2): 116-120, 1999.